Notably, a Brazilian research team investigated this compound's efficacy against multiple myeloma and identified its mechanisms of action involving the NF-kB and PI3K/mTOR/Akt pathways Fig. 15. The gene discussed is MTOR; the disease is plasma cell myeloma.